Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses
Year: 2026
Type: article
Abstract: Cytotoxic therapies such as chemotherapy and antibody-drug conjugates (ADCs) kill tumor cells directly but are limited by resistance, dose-limiting toxicity, and failure to induce durable antitumor immunity. Here we show that tumor-associated antigen (TAA)-targeted CD28 bispecific antibodies (TAAxCD28) convert cytotoxic agents into drivers of durable antitumor immunity. In humanized mouse models, combining the HER2-directed ADC trastuzumab deruxtecan (Tras-DXd) with TAAxCD28 antibodies enhances tumor rejection and promotes durable immune memory in Tras-DXd-resistant cancers, and comparable synergy is observed with 5-fluorouracil (5-FU). This therapeutic strategy allows lower or less frequent cytotoxic drug dosing, potentially limiting systemic toxicity. Mechanistically, TAAxCD28 antibodies promote the activation and expansion of clonally-restricted tumor CD8+ T cells, and adding ADCs or chemotherapy sustains this activation while preserving a naïve/stem-like pool of tumor-specific CD8+ T cells with a diversified T cell receptor repertoire. Each cytotoxic agent supports this T cell activity through a separate innate mechanism: Tras-DXd expands and activates conventional dendritic cells, whereas 5-FU reprograms suppressive myeloid cells toward an immunostimulatory phenotype. Together, these findings support pairing cytotoxic agents with TAAxCD28 bispecifics to overcome resistance and improve long-term tumor control in refractory cancers. TAA×CD28 costimulatory bispecific antibodies are a class of immunotherapeutics that provide tumor-targeted CD28 costimulation to T cells by crosslinking CD28 on T cells to a tumor-associated antigen (TAA) expressed on tumor cells. Here, the authors show that cytotoxic therapies reprogram the tumor microenvironment and augment the antitumor immunity induced by TAA×CD28 bispecifics.
Source: Nature Communications
Authors: Dylan Kwart, Qiaozhi Wei, Wei-Yi Cheng, Kamilah Ryan, Allen Leary, Jacquelynn Golubov, Ciara Torres, Patrick Poon, Jacqueline Warsaw, Jacob Lowy, Erica Ullman, Aynur Hermann, Jennifer Finney, Lauric Haber, Albert Canturri, Dharani Ajithdoss, Andria Skinner, Eric Smith, Christopher Daly, Jeremy Rabinowitz, Erin Paul, Nicole Stokes Oristian, William Poueymirou, Christina Adler, Min Ni, Namita T. Gupta, Frank Seebach, Melissa Mathias, Matthew Fury, Israel Lowy, William Olson, John C. Lin, Andrew Murphy, Bei Wang, Dimitris Skokos
Institution: Regeneron (United States)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,990
OpenAlex ID: W7233605038
